Abstract
Introduction
Bovine respiratory disease (BRD) complex is a leading cause of economic losses in the beef and dairy cattle industries. Mannheimia haemolytica is recognised as the primary pathogen associated with this disease. While antibiotics and vaccines are widely used against it, antimicrobial resistance and limited vaccine efficacy remain obstacles. Mannheimia haemolytica leukotoxin A (LktA) has been identified as a promising candidate for subunit vaccine development against BRD. However, the low expression and biological instability of the full-length LktA complicate its production. This study evaluated the immunogenic potential of the truncated LktA protein for subunit vaccine development.
Material and Methods
Truncated proteins of LktA N-terminal (nLktA) and C-terminal (cLktA) were expressed in E. coli which were small enough for stable expression yet large enough to function as effective immunogens. The immunogenicity of the recombinant truncated LktA proteins was evaluated in mouse and goat models against a phosphate-buffered saline (PBS) negative-control group. Recombinant cLktA was emulsified with oil adjuvant and used to immunise mice and goats.
Results
The cLktA group had significantly higher antibody levels at four weeks post-immunisation (wpi) than the PBS group. In goats, cLktA elicited high antibody responses up to six wpi. A single administration of cLktA conferred 80% and 100% survival against a M. haemolytica challenge.
Conclusion
These findings show the C-terminal region of Mannheimia haemolytica LktA to be a highly immunogenic and protective antigen and suggest its potential as a candidate for subunit vaccine development.